 |
 |

Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis
Results From a Randomized Placebo-Controlled Trial
Glenn Haugeberg, MD, PhD;
Anders Strand;
Tore K. Kvien, MD, PhD;
John R. Kirwan, MD
Arch Intern Med. 2005;165:1293-1297.
Background Bone damage in rheumatoid arthritis presents as osteoporosis and joint erosions. Prednisolone has been shown to reduce the rate of hand joint destruction as seen on radiography but has not been shown to reduce the rate of hand bone loss.
Methods In a double-blind study comparing oral prednisolone (7.5 mg/d for 2 years) with placebo, hand bone density assessed with digital x-ray radiogrammetry was examined in 95 patients with rheumatoid arthritis with disease duration of less than 2 years.
Results The mean loss of hand bone density was less in prednisolone-treated patients compared with placebo-treated patients at the 1-year follow-up (0.011 vs 0.022 g/cm2) (P = .005) and at the 2-year follow-up (0.026 vs 0.039 g/cm2) (P = .03). The mean percentage group difference in loss of hand bone density was 2.8% (P = .004) at the 1-year follow-up and 3.5% (P = .01) at the 2-year follow-up. In the first year, C-reactive protein, a marker of inflammation, was strongly correlated with hand bone loss in placebo-treated patients but not in prednisolone-treated patients, suggesting that prednisolone breaks the link between bone loss and inflammation.
Conclusions To our knowledge, this is the first double-blind randomized study to show that disease-related loss of hand bone density in rheumatoid arthritis can be decelerated by prednisolone. This finding suggests that the deleterious effect of prednisolone on bone may be counteracted by its anti-inflammatory effect.
Author Affiliations: Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway (Drs Haugeberg and Kvien and Mr Strand); and University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, England (Dr Kirwan). Dr Haugeberg is now with the Department of Rheumatology, Sørlandet Hospital, Kristiansand, Norway.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study
Hoff et al.
Ann Rheum Dis 2009;68:1171-1176.
ABSTRACT
| FULL TEXT
Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up
Hoff et al.
Ann Rheum Dis 2009;68:324-329.
ABSTRACT
| FULL TEXT
Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis
Guler-Yuksel et al.
Ann Rheum Dis 2009;68:330-336.
ABSTRACT
| FULL TEXT
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
Wijbrandts et al.
Ann Rheum Dis 2009;68:373-376.
ABSTRACT
| FULL TEXT
Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis
Guler-Yuksel et al.
Ann Rheum Dis 2008;67:823-828.
ABSTRACT
| FULL TEXT
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF{kappa}B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis
Vis et al.
Ann Rheum Dis 2006;65:1495-1499.
ABSTRACT
| FULL TEXT
Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database
Burnham et al.
Ann Rheum Dis 2006;65:1074-1079.
ABSTRACT
| FULL TEXT
Determinants of hyperkyphosis in patients with ankylosing spondylitis
Vosse et al.
Ann Rheum Dis 2006;65:770-774.
ABSTRACT
| FULL TEXT
|